Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Wire to Wire Daily Stock Picking -- Ignore unavailable to you. Want to Upgrade?

To: Jeffrey L. Henken who wrote (2270)	7/25/1999 6:17:00 PM
From: Mike McFarland	Read Replies (2) \| Respond to of 3514

MAGN - Mike McFarland - Float 14m -3 1/4 x 3 1/2 FDA aprvs Pex. I've no idea whether it will be approved or not, a total crap shoot...and my shares are paid for no matter what happens. There is a chance the decision will not come on Monday...but it should. If Locilex/Pex. is approved as a topical antibiotic for diabetic foot ulcers it will be on the order of a 200M/year drug and MAGN should trade in the teens later this year. If not...I see 1 1/2 as the bottom...they still have Squalamine--an anti- angiogenesis inhibitor in phase II lung cancer trails. See the thread for the precise details. Yahoo folks see this in the 30's on approval, nice, a ten bagger. I could be low on my upside target. Multiples of sales can get crazy when a ship comes in, but I find it hard to swallow that it would be trading at 3.5 when the odds are 50/50 of this being a ten bagger. I'd be real happy with $10-$12. Since I last visited the thread, NTII is still around 1 1/4...and IMHO, still a bargain if you don't mind the spread...but it is not tradeable.